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INTRODUCTION

The presence of diurnal variation in intraocular
pressure and pupil diameter and the frequently noted
association of endocrinological derangements with intra¬
ocular pressure abnormalities has led many investigators
to search for an endogenous hormonal modulator of these
ocular functions.

The products of the neurohypophysis

were early targets of this search.

In the past, however,

one was limited to relatively crude preparations of pos¬
terior pituitary extracts, which often led to variable and
contradictory results.

Today the investigator has at his

disposal not only highly purified and synthetic hormone
preparations but also a cornucopia of synthetic analogs
with selective properties that enable one to sort out the
complex activities of the native hormone.
This paper links

the old with the new.

Certain

ocular effects of neurohypophyseal peptides which have
been studied for years are brought up to date in the light
of current understanding of neurohypophyseal physiology
and peptide chemistry.

Then,

in turn,

recent findings

are incorporated in a discussion of the phylogeny of cer¬
tain aspects of the vertebrate visual apparatus.
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REVIEW OF THE LITERATURE

The Neurohypophyseal Peptides - General Aspects
The neurohypophysis of all vertebrate species studied
to date contains one or more structural analogs of the mamma¬
lian hormones,

vasopressin and oxytocin.

Thus,

the neuro¬

hypophyseal hormones constitute a phylogenetically old group
of neuropeptides.

1 2
’

(See figure 1)

Vasotocin

(AVT)

is

currently thought to have been the evolutionary precursor
of all other neurohypophyseal peptides and has been found
in the neurohypophysis of all vertebrates, except mammals.
Lower vertebrates usually have,

in addition to AVT,

other closely related oxytocin-like peptide.
neurohypophyses,

on the other hand,

and arginine-vasopression (AVP)
in which lysine-vasopressin

one

Mammalian

contain oxytocin

(OT)

-- except for order Suina,

(LVP)

is substituted for AVP.

Both AVP and OT differ from AVT by only one amino acid
residue; AVP is Phe^-AVT while OT is Leu^-AVT.
In 1954 AVP and OT became the first peptide hormones
to be sequenced and synthesized;

the other neurohypophyseal

peptides have since followed suit.

3

The naturally occurring

peptides are endowed with a complex set of potent pharma¬
cologic activities in varying relative proportions;

for¬

tunately a number of structure-activity relationships have
been elucidated through the use of synthetic analogs.
(Table 1)
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From this approach,

for example,

it has been learned that

the hexapeptide ring, which forms the structural backbone
of the molecule,

is essential to biological activity.

3

Spectroscopic methods have revealed very few differences
among the naturally occurring hormones with respect to this
backbone; vasopressins,

for example,

tend to display only

a slightly greater structural rigidity than do oxytocin-like
peptides.

4

However,

the amino acid residues at positions

3,4 and 8 are quite variable and the external orientation
of their side chains free them to interact with specific
receptor recognition sites.
these positions,

Amino acid substitutions at

along with a few other minor modifications,

have led to a host of synthetic analogs with pharmacologic
properties much more specific than those of the natural
peptides.

For example,

DDAVP

(1-deamino,

8-D-arginine-

vasopressin) has a much higher ratio of antidiuretic to
pressor activity than does AVP and is currently the treat¬
ment of choice in diabetes insipidus because of its greater
potency and therapeutic index.

3 6
’

Recently,

potent and

selective antagonists to the pressor effect have been syn¬
thesized; unfortunately, however,

a good antagonist to

the antidiuretic activity is still awaited.

(This topic

has been reviewed by Berde and Boissonnas/ and Manning
et al.^)
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Neurohypophyseal Peptides--General Physiologic Considerations
In mammals,

the neurohypophyseal peptides are synthe¬

sized by the magnocellular neurons
supraoptic (SON)

located primarily in the

and paraventricular (PVN) hypothalamic

9

nuclei.

From the neuronal cell bodies the hormones,

in

association with their respective carrier proteins or "neurophysins," are transported axonally within secretory vesicles
to the nerve endings in the posterior lobe of the pituitary.
Hormones are released by a calcium-dependent exocytotic
process triggered by depolarization of the nerve ending.^
Once in the bloodstream the hormones have a rather short
half-life--about ten minutes for AVP and one to several
minutes for OT--as they are rapidly degraded by plasma and
tissue aminopeptidases or are removed by glomerular filtration,

3,11
Only two well documented physiologically important

roles

have been found for the neurohypophyseal peptides--

the antidiuretic

(ADH)

action of AVT and AVP and the media¬

tion of the milk let-down reflex by OP.
The ADH activity appears

to be a result of an adenyl¬

ate cyclase-mediated increase in epithelial permeability
to water.

12 13
’

In land vertebrates

the targets for the ADH

effect are the collecting tubules in the kidney;

in addi¬

tion the skin and bladder of amphibians respond to ADH.
Release of the hormone occurs in response to volume deple-

■
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tion or a rise in plasma osmolarity beyond an endogenously
predetermined level.

Furthermore a variety of drugs

pecially anesthesia), hypoxia

14

, noxious stimuli,

ventricularly administered angiotensin
stimulate release.

15

(es-

and intra-

have been shown to

Failure to secrete sufficient ADH re¬

sults in inability to maintain a concentrated urine,

a con¬

dition known in man as diabetes insipidus.
Oxytocin has been shown to be essential for lactation.
Unlike the epithelial action of ADH,
effect on the myoepithelial cells

oxytocin’s contractile

lining mammary gland ducts

does not appear to be mediated by adenylate cyclase,
though guanylate cyclase may be involved.

16

Oxytocin also

has a potent contractile effect on the myometrium,
ly in the gravid uterus,

al-

especial¬

that is probably mediated by pros¬

taglandins.

Oxytocin may not play an essential role ih

parturition,

since successful labor can occur in its com¬

plete absence, but it almost certainly plays a facilitative
i
11
role.

Both AVP and AVT have potent cardiovascular effects
from which the name "vasopressin" was derived.

The pressor

response arises from a generalized vasoconstriction caused
by a direct calcium mediated action on vascular smooth
17
muscle.
This action has generally been thought to play
no important physiologic role since plasma levels of vaso¬
pressin at which antidiuresis is maximally stimulated
(10

-12

to 10

-11

M) produce no pressor response.

However,

.
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this concept is being challenged because of the following
findings:

hemorrhage and volume depletion can stimulate

release of AVP to the point where plasma levels are suffi¬
cient to produce a pressor response;

during inhibition of

baroreceptor reflexes by anesthesia, pressor responses can
be demonstrated at even lower concentrations of AVP than
previously thought;

12

in vitro studies have shown that the

post-capillary venules are the most sensitive component of
the vascular system to vasopressin,

suggesting that AVP

might have an important microcirculatory effect that would
not be adequately demonstrated by measurements of arterial
blood pressure."^

Some investigators have even argued that

vasopressin is an etiologic factor in essential hypertension.

12 18
’

In summary then,

an important physiological

role for AVP in circulatory homeostasis,
flow states,

cannot be ruled out.

muscle effects of vasopressin,

especially in low

On the other hand,

smooth

such as on intestinal, uter¬

ine and bronchial smooth muscle,

require high pharmacologic

concentrations and are probably of no physiologic importance.

19
The neurohypophyseal hormones have also been con¬

sistently shown to cause hyperglycemia in a wide range of
vertebrate species.

Pharmacologic doses are required for

this effect, which is apparently not mediated by cyclic
AMP.

20,21
A number of functions within the central nervous

'
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system have recently been ascribed to the neurohypophyseal
peptides;

this has been substantiated somewhat by anatomic

localization of significant amounts of vasopressin and neurophysins in various regions outside of the classic supraopticoand paraventriculo-neurohypophyseal pathways.
example,

10 12 22
’

’

For

one collateral pathway from the magnocellular

nuclei leads to the zona externa of the median eminence
where local release results in

very high concentrations of

AVP in the portal circulation to the adenohypophysis.
demonstration of this anatomical arrangement,
extensive pharmacologic studies,

The

combined with

has given credence to a

physiologic role for AVP in stimulating release of ACTH.

12 23 24
’
’

Demonstration of vasopressin in the hippocampus and parts
of the limbic system has bolstered experimental evidence in
rats that the neurohypophyseal peptides play important roles
in long-term memory consolidation and in development of
tolerance to opiates.

22 25 26
’

’

In addition,

both the pres¬

ence of a blood-CSF barrier to AVP and the poor correlation
sometimes found between simultaneous plasma and CSF hormone
levels under both normal and,
ditions

especially, pathologic con¬

(subarachnoid hemorrhage,

in particular) have been

regarded as evidence that AVP is secreted directly into
the CSF, where it may regulate the permeability of brain
capillaries to water.

27

’

9R

While it is fairly well established that vasotocin's
role in lower land vertebrates parallels that of AVP in

'

Page 8

mammals--both produce antidiuresis by an adenylate cyclasemediated alteration of epithelial permeability to water-its role in marine vertebrates is not understood.

Hampered

by our ignorance of the mechanisms of osmotic homeostasis
in these organisms,

investigators have been unable to find

an analogous effect on epithelial permeability, but have
noted potent effects on gill blood flow and glomerular
filtration rate.

Should these vascular effects of the

neurohypophyseal peptides prove to be physiologically impor
tant in the maintenance of osmotic homeostasis in the phylo
genetically older marine vertebrates,

the unexplained yet

potent vascular effects in mammals might easily be regarded
as vestigial.1
AVT may also act as a reproductive hormone in some
land vertebrates, probably in a facilitative capacity
analogous to oxytocin's role in mammalian parturition.

Endo

genous physiologic actions of the oxytocin-like peptides in
the lower vertebrates have yet to be identified.

1 2
’

The pineal gland of a number of vertebrates also
contains AVT.

Pavel and his coworkers,

on the basis of a

complex bioassay, have reported that all mammals that they
have examined to date--including man--contain AVT (except
for Suina, which have lysine-VT).

Specialized ependymal

cells in the pineal recess are involved in synthesis and
storage, while the pineal hormone melatonin triggers re¬
lease of AVT into the CSF,

from which it carries out its

*
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purported sleep-inducing and antigonadotrophic actions.
These findings could be explanatory for an extensive litera¬
ture detailing the pineal's involvement in circadian rhythms
and gonadal development.

33-35

Unfortunately, however,

attempts to confirm the presence of vasotocin in mammals by
highly specific radioimmunoassay have met with only varying
36 30
success.-3
Until this issue is resolved, Pavel's provoca¬
tive findings will have doubtful significance.

Neurohypophyseal Hormones and the Eye-Effects on the Pupil
Investigators early in the century began to examine
the actions of posterior pituitary extracts on the eye.
Their efforts were probably first inspired by the pupillary
effects of the adrenal medullary hormones.

Consequently,

and because of its easy accessibility to direct viewing,
the pupil became the earliest focus of ocular experimenta¬
tion with neurohypophyseal extracts.
of this early work,

The general consensus

summarized by Pollack in 1920, was that

Pituitrin (posterior pituitary extract)
mydriasis in the enucleated frog eye,
jected intravenously into mammals.

39

generally produced

and miosis when inPollack himself ob¬

served mydriasis after conjunctival instillation into
rabbit eyes, but miosis upon intravenous administration.
These early investigators were greatly hampered by
the state of ignorance concerning the multiplicity of active
principles in the neurohypophysis,

and by variability in

'
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commercially available crude extracts.

The separation of

the posterior pituitary extracts into vasopressin and oxyto¬
cin in 1928 served
vestigations.

Thus,

to facilitate further physiological in¬
Swan and Meyers in 1936, using the newly

commercially available posterior pituitary fractions,

found

that conjunctival instillation of Pitressin in the rabbit
would induce not a mydriasis, but an atropine resistant
miosis, while Pitocin would have no effect on the pupil.
On a historical note,

40

it might be of interest to

comment here that this discovery of a direct miotic action
of a peptide hormone occurred years before either Ambache's
isolation of irin in 1954 or the recent demonstration of
the miotic activity of Substance P.
Schlaeppi

(1940),

70 93
*

attributing the contradictory re¬

sults of the past to differing doses and routes of adminis¬
tration,

attempted to resolve the discrepancies by examin¬

ing the effects of intravenous,

subcutaneous,

subconjunctival,

and conjunctival instillation of Pitressin and Pitocin.

41

/V

While large doses of Pitressin in rabbits

(10 units

intra-

* Units of Pitressin (the purified extract) or vaso¬
pressin (the synthetic preparation) actually correspond to
units of pressor activity, tested by measuring the blood
pressure response of the rat; antidiuretic activity should
be identical to pressor activity unit for unit in Pitressin
or vasopressin.3
Unless otherwise specified, units of Pitocin (which
in this work refers to the purified extract) and oxytocin
(the synthetic preparation) are actually measured in an
avian vasodepressor bioassay, which parallels uterinestimulating activity.3

'

*
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venously,

1-10 units subconjunctivally or 5 units by in¬

stillation)

produced a marked atropine-resistant moisis last

ing several hours,
conjunctivally)
administration

small doses of Pitressin (0.05 units sub¬

produced a small mydriasis.

Subcutaneous

(5 units) produced a weak mydriasis peaking

within the first 45 minutes followed by a somewhat stronger
miosis.

This pattern was explained by the relatively slow

systemic absorption resulting from subcutaneous administra¬
tion, which results in a phase of low Pitressin plasma
levels

(manifested by mydriasis)

levels

(manifested by miosis)

from the injection site.

followed by higher plasma

as more Pitressin

Pitocin,

is absorbed

on the other hand, was

found to act like weak Pitressin, producing mydriasis upon
intravenous or subcutaneous administration (5 units)
no effects on the pupil when administered locally.

and

41

Schlaeppi also carried out some experiments in human
subjects.

Intravenous administration of Pitressin (8 units)

in man produced about 3mm of mydriasis, beginning after
two to three hours and lasting indefinitely.
Pitressin

(10 units)

also produced a long lasting mydriasis

but conjunctival instillation had no effects.
ly,

Subconjunctival

Corresponding¬

Pitocin, which acted like a weak Pitressin in rabbits,

had little or no effects in man.
Thus,

41

Schlaeppi's attempt to settle the issue of

vasopressin's pupillary effects seems to imply at least a
dual action--a dilatory effect in the low dose range and

Page 12

a constrictive effect that predominates in the high dose
range.

Besides a 1949 paper in which Zwiauer and Bornschein

mention in passing that they observed miosis following intra
venous injection of Pitressin

(10 units)

into rabbits,

no further studies on the neurohypophyseal peptides'

42

pupil¬

lary effects have appeared in the literature.

The Neurohypophyseal Peptides and the Eye--Theoretical
Considerations of Effects on Intraocular Pressure
Before tackling the experimental literature concern¬
ing vasopressin's effects on intraocular pressure

(IOP),

it

may be worthwhile to digress in order to comment on how vaso
pressin might plausibly act to produce its IOP effects.
Although a detailed discussion of aqueous dynamics will not
be undertaken here,

an attempt has been made to summarize

some particularly relevant points.

(Table 2)

A few aspects require further elaboration:
1)

The most reasonable targets for a physiological action

of vasopressin on IOP are the ciliary epithelium -- where
transport processes or water permeability may be regulated-and the outflow tracts-- where it may effect smooth muscle
or myoepithelial contractility.
2)

Vascular effects are unlikely to produce long-lasting

changes in IOP.

Volumetric changes, resulting from local

vasoconstriction or a sudden rise in systemic arterial pres¬
sure, have only transient consequences on IOP.

Furthermore,
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because aqueous humor formation depends primarily on ciliary
epithelial active transport and not ultrafiltration, moderate
changes in ciliary arteriole perfusion pressure and blood
flow would probably not significantly alter aqueous inflow.
Only in the unlikely event that vasopressin causes a lasting
vasoconstriction sufficient to elminate almost completely
the blood flow to the ciliary processes would aqueous humor
secretion be significantly reduced and a long-lasting effect
on IOP result.
3)

43

"Plasma osmolarity," "pupillary block," and "episcleral

venous pressure" are included for the sake of completeness.
Plasma osmolarity changes have well-established, but tran¬
sient,

effects on IOP.

Pupillary block could only become

significant if vasopressin exerted a strong miotic effect,
unlikely under physiologic circumstances.
act to raise central venous pressure,
venous pressure,
tion

(SIADPi)

Vasopressin may

and therefore episcleral

in pathologic states such as water intoxica¬

or shock, but also not under normal circumstances.

Because vasopressin might have multiple sites of ac¬
tion,

its net effect on IOP could vary considerably,

ing on dose and route of administration.

depend¬

The situation is

complicated further by the use of anesthesia, which can
significantly alter systemic and intraocular responses to
vasopressin.

(See Table 2)

With these considerations in mind,

it becomes clear

that experimental effects of vasopressin must be interpreted

.
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very cautiously, both with respect to mechanisms of action,
and with respect to implications for physiological signifi¬
cance.

It is hoped that some of the pitfalls of past inves¬

tigations can in this way be avoided.

Neurohypophyseal Peptides and the Eye--Past Investigations
of Effects on Intraocular Pressure
Numerous cases of abnormalities of IOP associated
with derangements in pituitary function appeared in the
literature in the early part of the century,

prompting a

search for a possible role for the neurohypophyseal hormones
in regulation of IOP.

41

These studies fell prey to the

same difficulties encountered in the investigation of
pupillary effects, but even more so, because of the greater
inherent complexity of IOP regulation.

The following example

illustrates this point.
Colle et al

44

administered Pituitrin

(3 units

travenously) in the intact anesthetized dog,

'V

in¬

and observed

a transient increase in IOP proportional to a simultaneous
transient rise in arterial blood pressure.
administering Pituitrin (5 units)
dog head preparation,

However, upon

in an isolated perfused

they instead noted a decrease in IOP

* Units of Pituitrin, the extract of the posterior
pituitary which contains both vasopressin and oxytocin,
are actually measured as units of oxytocic activity, which
parallels ADH activity.

'
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lasting for hours,

associated with a decrease in local tem¬

perature that to them indicated local vasoconstriction.
These experiments suggested to the investigators that
Pituitrin causes a vasoconstriction-mediated hypotensive
effect that is masked by its pronounced pressor effect in
the intact animal.

This explanation does not, however,

ex¬

plain why the same ocular hypotensive effect was not un¬
masked in the intact animal once the blood pressure had
receded to baseline levels.
in dose--three vs.
circulation vs.

In fact,

because of differences

five units--and pharmacokinetics--intact

an isolated perfusion system--the two ex¬

periments are not really comparable.

It might also be

noted here that anesthesia, used in the intact animal ex¬
periment,

tends to augment the pressor response to vaso¬

pressin by inhibiting the normal baroreceptor reflexes.
As with investigations of pupillary effects, vari¬
ability in the preparations of the hormones used for experi¬
ments may have contributed to discrepancies.
Cohen and Bothman

45

For example,

observed no changes in the choroidal

circulation of rabbits following intravenous injections of
Pituitrin

(1 ampoule).

In contrast, Wudka and Leopole

used the somewhat purer preparation Pitressin
per kilogram given intravenously)

46

(3-10 units

and observed, by direct

viewing through a plastic uveal window in the proptosed
rabbit eye,

an immediate and marked vasoconstriction that

especially affected choroidal arterioles and lasted several
minutes.

.

.

'

.

...

.
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A general consensus eventually began to develop con¬
cerning vasopressin's action on IOP.

Schlaeppi^ observed

consistent lowering of IOP in both man and rabbits following
administration of Pitressin,

even in doses as low as 0.05

units when injected subconjunctivally into rabbits.

Pitocin

was also observed to lower IOP in rabbits, but not in man.
In partial confirmation of these findings,
Christensen

47

observed lowering of IOP,

Becker and

lasting 2-3 hours,

following conjunctival instillation of Pitressin (2 units)
in both normal and glaucomatous eyes.

In both humans and

rabbits the hypotensive effect was parallelled by a decrease
in tonographically measured aqueous inflow, with observable
iridial vasoconstriction in the rabbit.

48

Moreover, upon

repeated administration resistance rapidly developed simul¬
taneously to Pitressin's hypotensive and vasoconstrictive
effects.

al

44

These studies,

combined with those of Colle et

and VJudka and Leopold,

46

all seemed to indicate that,

in pharmacologic doses, vasopressin lowered IOP and reduced
aqueous inflow, perhaps by means of a vasoconstrictioninduced lowering of ultrafiltration-dependent aqueous for¬
mation.
However,
develop.

a trend in the opposite direction began to

Reports appeared,

such as Weinstein's in 1950,

claiming that posterior pituitary extracts increased the
sensitivity of the response to the water provocative test
for glaucoma.

49

Although these claims were disputed by

'
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Leydhecker,

interest had been stimulated in the possibility

that vasopressin,

in lower and more physiologic doses,

acted to raise IOP.
To test this possibility, Houle and Grant investigat¬
ed the interactions of ethanol and physiological doses of
vasopressin on IOP.~^

Ethanol ingestion had previously

been observed to lower IOP in glaucomatous patients.

Since

ethanol produces a well known diuretic effect by inhibiting
release of AVP from the neurohypophysis,

it appeared reason¬

able that its ocular hypotensive effect might also be
caused by inhibition of AVP release.

Houle and Grant found

that subcutaneous administration of 0.5 units of vasopressin,
a dose that was calculated to produce maximal antidiuretic
but no vasoconstrictor effects,

did indeed prevent the

ethanol-induced lowering of IOP in glaucoma patients.
Furthermore,

the serum osmolarity changes did not in them¬

selves seem sufficient to account for the observed IOP
effect.

Therefore,

a physiological role for vasopressin

in maintaining IOP was suggested.
Various mechanisms for AVP's putative role in IOP
modulation were considered.

Cardiovascular effects required

high doses and so were probably not involved.

Alterations

in plasma osmolarity were being examined but seemed an un¬
likely explanation.

However,

an attractive hypothesis

arose by drawing a parallel between the ciliary epithelium

■'

.
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in the eye and the tubular epithelium of the kidney--perhaps
AVP exerted a direct epithelial effect on aqueous humor
formation,

just as it exerted a direct epithelial effect on

urine formation.
Berggren was unable to confirm this attractive idea
in his in vitro ciliary process preparation.
pressin (0.2 units per ml.

52

Neither vaso¬

of medium) nor oxytocin

(0.1 units

per ml.) had any effect on the rate of spontaneous ciliary
process shrinkage monitored photographically in vitro.
ever,

How¬

even Berggren himself pointed out that the technique

he used is better suited to demonstrate inhibition rather
than stimulation of ciliary process transport.
Subsequently,

though,

Cole and Nagasubramanian

succeeded in demonstrating that vasopressin can stimulate
short circuit current in an in vitro isolated ciliary body
preparation, using concentrations

low enough to be con¬

sistent with a physiological role for vasopressin in in¬
creasing aqueous humor formation in the rabbit. ^
to their hypothesis, vasopressin, which has

According

the property of

stimulating sodium transport in amphibian bladder epithelium,
also stimulates sodium transport by the ciliary epithelium
of the rabbit,

thereby increasing aqueous inflow and IOP.

This mechanism would serve the purpose of preventing falls
in IOP caused by dehydration or plasma hyperosmolarity.
further substantiate their arguments,

To

Cole and Nasasubraman-

lan performed the following additional experiments:

53

/
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1)

They compared the relative capacities of several vaso¬

pressin analogs to stimulate short circuit current,

and

found that the order of their relative activities-Pitressin = LVP > Phe

2

- Lys

their antidiuretic potency

8

8

-VP > Ornithine -VP--parallels

(on an ADH units to pressor units

basis).
2)

They expanded on the experimental model of Houle and

Grant‘d and showed that Pitressin,
in sub-pressor doses

administered intravenously

(400yU/kg/min), prevented the ocular

hypotensive effects of ethanol loading in rabbits,

indepen¬

dent of effects on serum pH or osmolarity.
3)

They showed correspondence between in vivo and in vitro

g
experiments by demonstrating that Orn -VP, which could not
effectively stimulate short circuit current,

also would not

prevent the ocular hypotensive effects of ethanol in rabbits.
Although their experiments do tentatively favor a
role for vasopressin in stimulating aqueous formation,
their arguments extolling the suggested parallels between
this activity and the ADH effect have several flaws.
of all,

there is

First

little or no evidence that vasopressin

stimulates epithelial sodium transport in the mammalian
kidney.

12

Secondly,

Bentley in 1967 showed that the

natriferic activity of synthetic vasopressin analogs in the
toad bladder correlated most accurately with pressor activlty and not ADH activity.

54

Finally,

Cole and Nagasubra-

manian confuse potency with efficacy when comparing the

.
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g
vasopressin analogs.

Only a four-fold higher dose of Orn -VP

is required to produce the same antidiuretic action as a
given dose of Pitressin in the kidney.^

On the other hand,

their data show no stimulation of short circuit current by
8
Orn -VP even in concentrations

10

5

times the threshold con¬

centration needed for Pitressin's stimulatory effect.
according to their data,

Thus,

the parallels drawn between vaso¬

pressin's renal and ciliary epithelial effects are not
really warranted.
However,

it is important to emphasize the essential

validity of their approach of combining a plausible in
vitro

assay with a fairly reliable and physiological in

vivo experimental model.
effects of the ethanol,

In fact,

despite possible side

this rabbit model is especially

attractive because probably the best way to demonstrate
physiological action of a substance is to remove or inhibit
the endogenous source before administering physiologic
amounts of exogenous material.
ian,

Unfortunately, Nagasubraman-

in further pursuing vasopressin's actions on IOP,

to adhere to this principle,
the pitfalls

failed

illustrating instead some of

encountered by not establishing a well for¬

mulated paradigm in carrying out research.
For example,

to rule out the possibility that vaso¬

pressin might be mediating its antihypotensive effect by a
decrease in outflow facility,

Nagasubramanian performed con¬

stant pressure infusion experiments over the range of 20 to

J
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35 mm Hg.

Intravenous infusions of vasopressin (400-1600yU/

min/kg) had no effect, while intracameral infusions at con¬
centrations of 50 yU/ml actually caused a decrease in out¬
flow facility.

However,

fundamental flaws in the experi¬

mental design are quite evident.
pressin's physiological role is

First of all,

if vaso¬

to prevent IOP from falling

to dangerously low levels under certain conditions,

then

possible effects on outflow facility should be examined at
tensions below 20 mm Hg.

Furthermore,

vasopressin had been

shown to produce an ocular hypotensive effect in rabbits
only if endogenous vasopressin release had been suppressed
by ethanol pretreatment.

53

Perhaps vasopressin has an

effect on outflow facility that is similarly dependent on
pretreatment with ethanol.

Nagasubramanian, however,

only

measured effects on outflow facility in rabbits that had
not been treated with ethanol.

Therefore, his experiment

does not really address itself to the important question he
set out to answer.
In addition,

some experiments are burdened with the

use of nicotine to stimulate secretion of endogenous vasopressin in ethanol loaded rabbits.
and complex autonomic effects,

56

In view of its potent

though,

it is unclear what

advantages nicotine has over physiologic administration of
vasopressin in the in vivo experimental model.
Other experiments,

employing close-arterial and in¬

travenous infusions of vasopressin,

attempt to correlate

'
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changes in IOP with simultaneous changes in systemic arterial
pressure and thermocouple-monitored uveal blood flow in the
anesthetized rabbit.

56

The results confirm the previously

held opinion that in high doses vasopressin lowers IOP in
association with reductions in uveal blood flow.
reductions

However,

in ciliary process blood flow are not thought to

diminish aqueous humor secretion unless blood flow is re¬
duced to extremely low levels.

Therefore,

since these

experiments do not provide absolute values for ciliary pro¬
cess blood flow rates,

one cannot determine if the blood

flow reductions are sufficient to account for decreased
aqueous production and lowering of IOP.

Nagasubramanian

also employs infusions of physiologic doses of vasopressin,
which reportedly produce neither IOP changes nor changes
thermocouple readings.

These experiments, however,

in

do not

rule out possible effects of vasopressin on microcirculatory distribution within the uvea; changes in which would
not necessarily alter the net uveal blood flow rates moni¬
tored by the thermocouple.
In the following study,

Niederer et.

al.~^ draw a

conclusion opposite to that of Nagasubramanian

56

regarding

the mechanism of the ocular hypotensive effect of pharma¬
cological doses of vasopressin.

In this experiment,

aqueous

humor production is measured by monitoring 1-125 clearance
from the anterior chamber using a collimated-beam photo¬
multiplier.

The investigators report that a pharmacologic

'

'

,
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dose

(0.5 units)

of LVP injected intravenously into the

anesthetized rabbit produces a significant decrease in
aqueous formation that lasts about twenty minutes.

Because

the observed rise in systemic arterial pressure dissipates
within only five minutes,

the experiment is interpreted as

an indication that LVP's inhibition of aqueous formation
is mediated by a direct effect on the ciliary epithelium.
Unfortunately, neither do the authors provide any absolute
values for aqueous humor formation nor do they monitor IOP;
therefore it is difficult to assess whether a nociceptive
response had occurred following the many intracameral injec¬
tions used by the investigators for mixing.

Interpretation

is further complicated by the use of urethane anesthesia
and atropine pre-medication,
autonomic effects.

both of which have potent

Host importantly,

a systemic pressor

response is an insensitive indicator of local vasoconstric¬
tive effects."^

Therefore,

the interpretation of Nieaerer

et al cannot be justified on the basis of their data alone.
Recently,

Gregory et al

73

have studied the effects

of vasopressin on adenylate cyclase activity in broken and
intact cell preparations of rabbit ciliary processes.
pressin,

Vaso¬

in a wide range of pharmacologic concentrations,

did not significantly affect the adenylate cyclase activity
of ciliary processes,

despite the fact that in the same in

vitro system vasopressin caused a 36-fold rise in adenylate
cyclase activity of toad bladder epithelium.

The findings
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of Gregory et a_l argue against the possibility that vaso¬
pressin exerts an ADH -

like action upon ciliary epithelium.

To summarize briefly,
doses seems

Pitressin or LVP in large

to lower IOP^ ’ ^ ^ except when a systemic

pressor response is induced.

44

Evidence has been presented

to purport that this effect is mediated either by vasoconstnction,

by a direct epithelial effect,

or

conceivably by an increase in outflow facility,^ but al¬
most certainly not by activation of ciliary epithelial
adenylate cyclase.
may have no effect
sodium transport,

73

Physiologic doses,

505256
’

53 56
’

’

on the other hand,

or may promote ciliary epithelial

thereby stimulating aqueous formation,

observed in vivo only when endogenous hormone levels have
been suppressed by ethanol.

51 53
’

In relation to the

pupillary effects of vasopressin,
more prominent,

the IOP response seems

since investigators have usually failed to

comment on any pupillary changes.
As for other neurohypophyseal peptides,
has been noted in large doses
in IOP and slight mydriasis.

41

oxytocin

to produce a small decrease
Neither vasotocin nor any

of the newer potent and selective agonists and antagonists
have been examined for effects on the pupil or IOP.

Neurohypophyseal Peptides and the Eye--Some Untried
Experimental Approaches
With the advent of synthetic preparations of many

'

■
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peptide hormones,

it has often been rewarding to re-examine

phenomena which were studied in the past using crude ex¬
tracts that may have possibly contained unknown contaminants.
This point is especially pertinent to the pupillary effects
of the neurohypophyseal hormones, which have not been ex¬
tensively studied since 1940.
In addition,

because the neurohypophyseal hormones

have multiple and complex pharmacologic activities,

synthetic

analogs have proved to be very useful in sorting out their
diverse physiologic actions.
a nonpressor analog,
effects,

Johnson,

For example, by using DDAVP,

to separate antidiuretic from pressor

e_t al were able to demonstrate that AVP-

induced inhibition of renin secretion and increase in renal
electrolyte excretion are not secondary to increased tubular
permeability to water.

58

Bentley used analogs with varying

ratios of pressor to antidiuretic activity to illustrate
differences in the receptors mediating water permeability
and sodium transport in the toad bladder.

54

Keppens and

De Wulf used a variety of synthetic pressor agonists and
antagonists to confirm that vasopressin-induced hepatic
glycogenolysis is probably not mediated by an ADH-like
receptor and correspondingly not mediated by adenylate cyi
21
clase.

To this author's knowledge, no work has been pub¬
lished using DDAVP to examine vasopressin's mechanism of
action on IOP or the pupil.

DDAVP has a ratio of antidiuretic

-

■
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to pressor activity of from 79 to 4500
dose used)

(depending upon the

in contrast to AVP' s ratio of about 1.

The

8-D-arginine residue somehow contributes to functional
selectivity of the molecule by stabilizing its backbone
through increased steric hindrance."*

DDAVP is also a more

potent antidiuretic agent than AVP on a molar basis and
has a longer duration of action because deamination at
amino acid position 1 prevents its normal enzymatic degrada¬
tion in target organs.

Furthermore,

tivity is negligible.

Therefore,

DDAVP's oxytocic ac¬

significant ocular actions

of DDAVP would most likely be mediated by ADH-like receptor
mechanisms,

since pressor effects will be reduced consider-

ab ly.
Another approach would entail the use of selective
antagonists to vasopressin.

Although there are still no

efficient antagonists to ADH activity,

several highly selec¬

tive and potent antagonists to the pressor activity have
recently been synthesized.
dCCl^)^“Tyr-(Me)-AVP,

The most potent to date is

synthesized by Maurice Manning's group

at the Medical College of Ohio.
"PA2" or 8.67 + 0.02

(i.e.

It has an antivasopressor

50% inhibition of pressor re¬

sponses in rats occurs at antagonist concentrations
10

“8 62
'
M)

and also exhibits a protracted effect.

of

Furthermore,

it is not endowed with any ADR antagonist activity and has
very low agonist activity
diuretic assays.

59

(0.31 units/mg)

in rat anti-
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Besides using pharmacological approaches to sort out
mechanisms of response to neurohypophyseal hormones in vivo,
one might also benefit from employment of in vitro methods
to eliminate sources of variability.
be studied ideally in vitro,
by Soloway,

et al.

^

Pupillary effects can

as demonstrated by Sears

60

and

The well studied effects of the auto¬

nomic nervous system and circulating catecholamines,

as

well as the less understood mechanisms of nociceptive
responses,

could potentially mask direct effects of ex¬

perimental agents on the pupil.

Furthermore, vasopressin's

vascular actions might also indirectly effect the pupil¬
lary response.

By eliminating these sources of complica¬

tions, by providing a convenient means for precise adjust¬
ment of peptide concentrations and by allowing sensitive
and quantitative continuous monitoring of pupil responses,
in vitro studies can greatly add to our understanding of
vasopressin's actions on the pupil.
Finally,

a variety of agents with known or suspected

ocular actions can be used in conjunction with the neuro¬
hypophyseal peptides to preclude systematic errors.
more,

Further¬

comparison of the actions of other neuropeptides with

those of neurohypophyseal peptides may prove especially
fruitful when attempting to assess physiological or phylo¬
genetic significance.
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EXPERIMENTAL

Introduction

The broad experimental objective of the present work
is to establish methodological guidelines for characteriz¬
ing receptor mediation of intraocular actions of the neuro¬
hypophyseal hormones and possibly other neuropeptides.

This

approach involves thoroughly characterizing, with the help
of in vitro studies,

one relatively simple effect--pupil-

lary constriction--that can be used as a reference point
for investigating more complex actions,

such as those on

IOP.
Specific experimental objectives include:
1)

Investigation of the effects of neurohypophyseal pep¬

tides on the pupil through the use of an isolated iris
preparation.
2)

Characterization of the receptor mediation of the in

vitro response through the use of analogs and a potent,
highly selective synthetic antagonist.
3)

Examination of the effects of pharmacologic agents on

the responses to neurohypophyseal peptides in vitro,

in

order to rule out possible mediation of the response through
indirect mechanisms.
4)

Comparison of the actions of neurohypophyseal peptides

with putative peptide mediators of pupillary responses.
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5)

Establishment of basic dose-response curves for the

effects of intravitreal injections of neurohypophyseal pep¬
tides on the pupil and IOP, with emphasis on the use of
DDAVP to separate vascular from non-vascular mechanisms.

Materials and Methods

The following chemicals were used: Lysine-vasopressin,
oxytocin, vasotocin,

arginine-vasopressin,

substance P,

saicin, met-enkephalin, bradykinin triacetate,
acetyl-B-methyl-choline bromide,
Tween-20

(Sigma,

St.

Louis),

indomethacin,

1-phenylephrine hydrochloride,

substance P-fragment 4-11 octa-

peptide, neurotensin (Boerhinger-Mannheim),
arginine-vasopressin (DDAVP,
ceuticals),

cap¬

l-deamino-8-D-

Desmopressin, Ferring Pharma¬

and d^I^) ^Tyr-(Me) AVP ,

a synthetic vasopressor

antagonist which was the generous gift of Dr. Manning.

All

peptides used were synthetic with the exceptions of vaso¬
tocin and met-enkephalin.
In all experiments,

2 to 2% kg male New Zealand

albino rabbits were used.

The in vitro Isolated Iris Preparation
Isolated iris preparations have proven useful to
numerous investigators for determining pupillary responses
to pharmacologic agents in the absence of interfering autonomic and vascular effects.

60

The present in vitro system

is essentially identical to that used by Soloway et: al to

*
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investigate the actions of substance P on the iris.

Dissection Procedure
Anesthesia (urethane,

1,5-2 g/kg given intravenously)

was used to permit enucleation in the live animal and ensure
viability of the second iris hours later. Most animals also
received sodium indomethacin (50 mg/kg given intravenously)
at least 15 minutes before enucleation to prevent interfer¬
ence of endogenously-synthesized prostaglandins in the post¬
mortem pupillary response.
After enucleation the cornea was circumferentially
excised.

Six longitudinal incisions from the posterior

pole were made,

creating six triangularly shaped scleral

flaps arranged hexagonally around the iris,
scleral margin from the limbus.

leaving a 3mm

The lens and any remaining

vitreous were gently brushed away,

and the preparation was

pinned to a paraffin-covered cork surface, whereby the
iris was stretched to a uniform circular shape.

Two plastic

0-rings with perforating connecting needles were used to
mount the specimen through its scleral margin,

thus allowing

free movement of the iridial muscles. After placement in
the perfusion chamber housed within the spectrophotometer,
perfusion was immediately begun.

Elapsed time from enuclea¬

tion to perfusion was about 10-15 minutes.
In one experiment,
dilator muscle preparation,

in order to obtain an isolated
the same procedure was carried
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out,

save for the use of a 5mm trephine to remove the

sphincter muscle.

Perfusion System
The 1.2 ml iris chamber was

continuously perfused at

a rate of 3 mg/min with a modified Krebs-Ringer bicarbonate
buffer solution
moles/liter) :

62

with the following constituents

NaCl 118,

1.3, MgSO^ 1.2,

NaHC03 25,

glucose 10,

(in milli¬

KC1 4.8, KH2P04 1.2,

ascorbic acid 1.0.

CaCl

Oxygenation

and a pH of 7.3-7.4 were maintained by equilibration with a
gas mixture of 95% 02/5%, C02-

A water bath was used to pro¬

vide a constant chamber temperature of 25°C, monitored by
a thermometer placed at the chamber outlet.

A peristaltic

pump maintained constant perfusion rates.
In this system, which combines high oxygenation with
rapid clearance of metabolic products,
viable for hours,

the iris remains

as judged by its continued responsiveness

to pharmacologic agents.
In a few experiments some modifications were made.
Tween-20

(0.5 mg/liter) was included in the perfusion solu¬

tion in a few of the later experiments to retard adsorption
of peptides to tubing.

Slower perfusion rates

(l.Omg/min)

were sometimes used to prevent rapid clearance of pharmaco¬
logically released peptides.

Employment of any of these

modifications will be noted when reporting results.

.

Page 32
Infusion of Test Substances
Perfusion buffer was used to make up peptide solu¬
tions which were delivered at precise infusion rates bycalibrated,

silicone grease-coated Hamilton syringes,

by two independent Harvard pumps,
infusions of up to 3 compounds.

driven

allowing simultaneous
Steady-state chamber con¬

centrations were calculated by dividing the infusion rate
of the compound (in moles/min) by the chamber perfusion
rate

(usually 0.003 liters/min).
In many experiments,

were employed

(see below).

60 second infusions of peptides
In order to determine the pharma¬

cokinetics of this technique,

infusions of CoC^ solutions

into the chamber were monitored spectrophotometrically by
this author and found to obey first-order kinetics,
firming previous studies

61

con-

that employed fluorescein to

demonstrate complete chamber mixing.

Therefore,

the chamber

concentration C of a test substance at any given time after
starting or stopping an infusion is described by differ¬
ential equations

(1)

and (2),

calculated expliticly using

(1)
(la)

dC _ r
r
dt
LI V

C=CI

,

,

respectively,

(la)

and (2a),

(2)
-It

( 1-e V

(2a)

and can be
respectively

dC _
dt

r r
V
-£t

C = cFe V

represents s teady-s-tate infusion concentration.

'
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CF represents the final chamber concentration achieved at
the end of an infusion; V is the chamber volume
r is the perfusion rate;
or stopping the infusion.
rate is 3ml/min,

(1.2 ml)

and

t is the elapsed time after starting
Accordingly, when the perfusion

92% of steady-state chamber concentration

should theoretically be achieved by the end of a 60 second
infusion,

after which rapid wash-out occurs.

For simplicity,

the doses used in one-minute infusions will always be re¬
ferred to by their corresponding steady-state chamber con¬
centrations .
Pupillometrie System
Continuous pupil measurement was made photometrically
by a Carey 16 spectrophotometer,
of 540nm and a 3mm slit width.

using a wavelength setting

Holes of various known dia¬

meters were used to establish a standard curve which demon¬
strated a highly linear relationship between diameter and
"7, transmittance."

A calibrated chart recorder was used

to continuously monitor absorbance.

Absorbance values read

from the chart were converted, using Beer's law,

directly

to "70 transmittance" which was used to calculate pupil
diameter from the standard curve.

This system thus provided

a continuous permanent record of pupil diameter;

changes in

diameter as small as 25 microns could be reliably detected.
Baseline pupil diameter showed a high degree of
variability between preparations,

ranging from about 2.5 to

'

*
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5mm.

Semmlow et al demonstrated in humans that "pupillo¬

motor gain" varies with baseline diameter,

peaking at 4 to
^3

6 mm and tailing off at smaller baseline diameters.
Therefore,

^/

’

in order to compensate for variability in respon¬

siveness, pupillary changes are expressed as a percentage
of baseline diameter.

Technique of Infusion
After placement in the perfusion chamber,

the iris

was left to equilibrate for about 10 minutes and usually
_

Phenylephrine

then infused continuously,

often producing a further increase

in pupil diameter.

(1 x 10

£

displayed a slow dilation.

M) was

This low dose of phenylephrine was usually

used throughout the rest of the experiment to provide dila¬
tor tone, which facilitated a return to baseline following
constrictions.

Finally,

baseline diameter,

after the pupil achieved a stable

experimental infusions were begun.

Pre¬

parations with baseline diameters of less than 2.5 mm were
discarded.
Three modes of experimental infusions were used.
One method employed a 60 second infusion of test compound,
after which the maximum resulting change in pupil diameter
was noted.

When the pupil returned to baseline diameter,

another infusion could be begun.

Infusions were separated

by at least 12 to 15 minutes in attempt to avoid tachyphy¬
laxis.
sponses,

This technique produced fairly reproducible re¬
and was employed for establishing dose

response

■

.
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curves to compare relative potencies of peptides.
Continuous infusions were sometimes employed,
allowing the pupil to achieve a steady-state response to an
equilibrium concentration of peptide.

Although fairly long

infusions were often required before the pupil achieved a
steady state response,

the technique did maximize sensitivity

to a given concentration of compound and therefore this par¬
ticular approach was used to compare response-threshold con¬
centrations of various peptides.
Infusions of intermediate duration were sometimes
employed when it was desirable to increase response sensi¬
tivity without waiting for achievement of a steady-state
response.

Isolated Iris F.esponses to Neurohypophyseal Peptides

Pupil responses to AVP, LVP, AVT and OT were de¬
termined using 60 second infusions.

In addition,

responses

to continuous infusions were obtained for AVP and AVT.

Effect of Vasopressor Antagonist

In one preparation,

d(CI^)(Me)-Tyr-AVP was tested

for its effectiveness in antagonizing responses of the pupil
to LVP and substance P-octapeptide.

Isolated Iris Dilator Muscle Preparation
Responses of the pupil to LVP were tested in one
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iri's in which the sphincter muscle had been removed with
a trephine.

Viability of the preparation had been tested

with phenylephrine.

Isolated Iris Responses to Other Neuropeptides
Pupillary responses to 60 second infusions of sub¬
stance P

(SP),

SP-octapeptide, bradykinin, neurotensin,

met-enkephalin were tested.

Because pupil responses to

bradykinin, neurotension and met-enkephalin were weak,
mediate-length infusions

and

inter¬

( > 60 seconds) were also employed

to increase response-sensitivity.

Indomethacin Pretreatment
Indomethacin pretreatment

(see "Dissection Pro¬

cedure") was sometimes withheld to determine what effects
endogenous prostaglandins might have on the in vitro pupil¬
lary responses to neurohypophyseal peptides

(AVT and LVP)

and bradykinin.

Capsaicin Depletion Experiments
Capsaicin is known to deplete primary sensory
neurons of substance P,

65

and may reduce the magnitude of

both the ocular nociceptive response to nitrogen mustard
and neurogenic

67

or bradykinin induced

68

66

inflammation in

the skin.
Capsaicin was used here to produce a pharmacologic
"sensory denervation" in vitro,in order to determine whether
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sensory neurotransmitters are involved in the pupil's re¬
sponses to vasopressin and other peptides.

Capsaicin pro¬

duces its own miosis in vivo, which probably is mediated by
released neurotransmitters.

69

This phenomenon greatly facili¬

tated "chemical denervation" in the in vitro system.
ions of capsaicin

Infus¬

(usually about 0.4mg/ml for 10-20 seconds)

were simply repeated until they failed to produce pupillary
constriction,

at which point the preparation was assumed to

be pharmacologically denervated.
rates

Note that slow perfusion

(1 mg/min) were used during these capsaicin infusions,

in order to retard clearance of the released neurotransmitt¬
ers and thereby accentuate the pupillary constriction, which
as a result provided an even more sensitive guide to adequate
neurotransmitter depletion.
Pupil responses
kinin,

to various peptides

(LVP, brady-

substance P) were then determined in the "sensory

denervated" preparation.

Effects of Neurohypophyseal Peptides on Pupil Size and IOP
in vivo

In deciding upon the route of administration for
investigating the actions of the neurohypophyseal peptides
on the pupil and IOP,

several alternatives were considered.

Intravenous administration is probably the most physiologic
route of administration, but can produce systemic effects
that may confuse interpretation of the results.

Systemic

■
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complications can be somewhat reduced by using close-arterial
infusions.

This technique, however,

suffers from technical

difficulty and the need for general anesthesia.

Intracameral

administration is also technically difficult, has a high
risk of activating ocular nociceptive mechanisms,
probably not physiologic.
not physiologic;

and is

Conjunctival instillation is also

it most probably leads to considerable

systemic absorption and provides very uncertain pharmacologic
delivery.
The intraocular responses to neurohypophyseal
peptides

(LVP, AVT,

OT and DDAVP)

and substance P were deter¬

mined following intravitreal injections.

This route of ad¬

ministration was chosen for the following reasons:
1)

simplicity

2)

availability of the contralateral eye as a control

3)

the relative avascularity of the vitreous minimizes
systemic absorption

4)

lack of necessity for general anesthesia.

The main objections are:
1)

there is uncertain pharmacologic delivery to the sites
of action

2)

there is

the danger of traumatizing the eye

3)

it is probably a non-physiologic route of administration.
The first objection is dealt with by using intra¬

vitreal injections of substance P as a control since its

'

'
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molecular weight is similar to that of the neurohypophyseal
peptides,

and its actions on IOP and pupil size, via other

routes of administration, have been well characterized.^^5
Meanwhile,

an effort is made to minimize the second objection

by care in the technique and examination of the eye for signs
of traumatic injury.
Finally,

the present work does not attempt to es¬

tablish physiologic roles for the neurohypophyseal peptides;
instead,

the emphasis is first placed upon characterization of

pharmacologic responses by using relatively large doses and
rather artificial means of administration.

Intravitreal Injections--Procedure
The rabbit was calmed and the eye proptosed by
exerting pressure with the blunt end of a cotton tip appli¬
cator just above the inferior orbital rim while simultaneous¬
ly exerting digital counter traction on the superior aspect
of the globe through the upper lid.
tion of a local anesthetic agent

Then,

after instilla¬

(0.5% proparacaine HC1)

at the injection site, usually about 5mm from the limbus,
10 yl of fluid were delivered intravitreally using a Hamilton
precision syringe fitted with a 30 gauge needle.
taken to avoid obvious large surface vessels,

Care was

and the needle

was directed slightly posteriorly in order to avoid hitting
the lens.

After the injection,

all pressure on the globe

or orbit was removed and the needle swiftly withdrawn to

’
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prevent extrusion of vitreous.
In each rabbit,

the right eye received the test

substance diluted to the desired concentration with isotonic
saline.

The left eye received an injection of saline and

served as a control.

Pre-injection baselines of IOP and pup

diameter were recorded,
diameter,

and after the injection IOP,

pupil

and any signs of ocular irritation or injury were

recorded.
IOP measurements were made using an Alcon Applana¬
tion Pneumotonometer which had previously been manometrically calibrated versus water for the rabbit eye.
HC1

Proparacaine

(0.5%) was instilled conjunctivally in each eye before

tonometry.
Pupil size was estimated by eye under ordinary
room lighting conditions.

Special care was taken to provide

equal illumination to both eyes because the rabbit's pupillary light reflex displays poor consensuality.

72

Analysis of Data
Among structural analogs of the neurohypophyseal
peptides, when one pharmacologic activity parallels another
(e.g.

avian vasodepressor parallels oxytocic;

parallels pressor)

glycogenolytic

the two activities are thought to be

mediated by the same or a similar receptor.

21

The present work attempts to determine whether

.

.
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the receptor by which vasopressin exerts its pupillary effect
is closely related to the receptor for either pressor, ADH,
or oxytocic activities.

The approach is to statistically

analyze the correlations between pupillary effects and pep¬
tide doses, when doses are expressed as units of either
pressor, ADH,

or oxytocic activity;

conversions from moles

to units of activity are based upon values from the litera¬
ture.

(Table 1)
Two mathematical models are used.

One model employs

linear regression analysis of the relationship between pupil¬
lary response

(the dependent variable)

and the logarithm of

the dose; high covariance exists among the independent var¬
iables -- log units of pressor, ADH,

and oxytocic activity --

so that both simple and multiple regression analysis

is per¬

formed .
The other model attempts to compensate for obvious
anatomical features which impose theoretical limits on pupil¬
lary response by employing the algebraic formalism of the
Michaelis-Menten equation;

"V
" can be set at an appropmsx

riate maximal pupillary response.

The formalism is carried

further by the use of the "Lineweaver-Burk" equation to ex¬
press the dose-response relationship in such a manner that
both simple and multiple linear regression analysis can be
performed.

Such analysis derives a value for "K^" which is

strictly defined in the present study as the dose of neuro¬
hypophyseal peptide needed to evoke a half-maximal pupillary
response.

'
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RESULTS

Response of the Isolated Iris to Neurohypophyseal Peptides
All four neurohypophyseal peptides examined in vitro
(AVP, AVT,

LVP and OT) produced dose dependent pupillary

constriction.

Figure 2 clearly shows the relative potencies

of the peptides

(on a molar basis)

using 60 second infusions.

A similarly obtained dose-response curve to substance P is
included for comparison.

Typical tracings from the chart

recorder illustrate the time-course of the response

(figure

3).
Continuous infusions of the two most potent agents,
AVP and AVT, produced pupillary responses at threshold con¬
centrations of 1 x 10
spectively

(n=l)

(figure 2).

(n=2) ,

re¬

As a comparison it is interesting

to note that Soloway et al
tion of 2.3 x 10

and 2 x 10

61

observed a threshold concentra¬

for substance P effects in the same in

vitro system.
A cursory examination of figurd 2 reveals that the
relative potencies of the neurohypophyseal peptides in pro¬
ducing pupil constriction correspond to their relative
pressor activities:

AVP > AVT > LVP > OT.

This relation¬

ship is further examined by converting infusion concentra¬
tions to units of either pressor,

ADR,

or oxytocic activity

using values obtained from the literature

(Table 1).

Figures

4 and 5 display in this manner the results obtained with ail

'

Page 43

four neurohypophyseal peptides.

The aggregate relationship

displays a high degree of linear correlation with pressor
activity:

R=0.818,

95% confidence levels are 0.681 - 0.900,

standard error of estimate = 7.687 % constriction.
degree of correlation with oxytocic activity

A small

(P. r 0.44), was

found by multiple regression analysis to be accounted for
by covariance with pressor activity

(.418)

(figure 5).

It

should be noted that because ADH activity equals pressor
activity in all the peptides used for in vitro studies,

it

is theoretically impossible to separate the two effects in
this analysis.

However, ADH activity will be shown to be

a rather weak determinant of pupil size.
Another approach used to describe the data was based
upon mathematical modeling
kinetics.

akin to Michaelis-Menten enzyme

This model may have more intrinsic biological

relevance than rather arbitrary linear models.
V ("enzyme velocity")
striction," while S
as pressor units;
constriction.

is adapted to describe "%> pupil con¬

(substrate concentration)

The dose-response relationship is displayed
(Figure 6);

reveals a correlation coefficient
limits 0.688-0.909,p<.001)

regression analysis

(R=0.828,

95% confidence

slightly higher than the one ob¬

tained above with the simple linear-log model.
±

1.65 pressor units/liter

mately 12

-t

is expressed

a value for "V"max is assigned at 90% pupil

as a Lineweaver-Burk plot

13.46

The variable

1.5 nM for AVP)

A "K^" of

(corresponding to approxi¬

is obtained with this analysis.
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Isolated Dilator Preparation
The isolated dilator preparation did not respond to a
6 minute infusion of LVP at 5 x 10 ^M,

a dose that produces

a maximal constriction in the intact preparation.

The iso¬

lated dilator preparation did respond appropriately to an
infusion of phenylephrine

(1 x 10 ^M) by dilating 4.87,,

thereby demonstrating viability of the preparation.

The Effects of a Vasopressor Antagonist on the Isolated Iris
At concentrations as high as 2 x 10
by itself produced no pupillary response.
minute infusion of antagonist

the antagonist
However,

a four

(1 x 10 ^M) produced a 257>

_g
dilation during a continuous infusion of LVP
Furthermore,
(2 x 10 ^M)

(1 x 10

M).

during continuous infusions of antagonist

all responses to LVP

(up to 1 x 10 ^M,

continuously), were completely abolished.

infused

Furthermore,

even

after the infusion of antagonist had been stopped, responses

_g
to LVP

(2.5 x 10

M,

60 second infusions) were abolished for

at least 15 minutes.
This antagonistic activity was specific for vasopressin
agonists;

the antagonist in concentrations up to 4 x 10

had no effect on responses to substance P octapeptide.

Response of the Isolated Iris to Other Peptides
Responses to 60 second infusions of substance P were
generally in good agreement with the data of Soloway,
(see figure 2).

et al.

61

.
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Substance P-(4-ll)

octapeptide produced dose-dependent

pupil constriction as well.

Its potency was comparable to,

if not slightly greater than,
preparation,
60 sec.

for example,

that of substance P;

substance P octapeptide

in one
(1 x 10

-

8

M,

infusions) produced constrictions of 32.46 + 1.7 870

(mean + S.E.M.).
Sixty second infusions of bradykinin produced pupillary

_g
constrictions at concentrations as low as 1 x 10
the response was subject to rapid tachyphylaxis

M, but
(figure 7).

Furthermore, bradykinin demonstrated markedly reduced potency
after Tween-20 had been incorporated into the buffer solution.
Neurotensin produced only weak constrictions

(3.22-

4.817o) at relatively high concentrations (4 x 10 ^M, 3-5
minute infusions)

in one preparation.

Met-enkephalin produced no consistent pupillary re¬
sponses in concentrations as high as 4 x 10
infusions)

(60 second

in four separate preparations.

Indomethacin Pretreatment
Withholding indomethacin pretreatment produced no sig¬
nificant differences in responses to AVT
(two animals)

or bradykinin

(one animal),

LVP

(two animals).

Capsaicin Induced Densensitization
In five preparations,

the mean pupillary constriction

produced by in vitro capsaicin treatment was 38.11

(+ 4.86)%.

'
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These "denervated" preparations continued to respond nor¬
mally to phenylephrine,

LVP,

and substance P octapeptide.

However, pupillary constriction in response to bradykinin
(6 minute infusion at 10 ^M) was abolished in a "denervated"
preparation, while a 12°/0 constriction was observed in the
"non-denervated" isolated iris of the same animal.

Pupillary Responses to Neurohypophyseal Peptides in vivo
All four neurohypophyseal peptides tested
OT,

DDAVP) produced a dose-dependent miosis

(AVT,

LVP,

(figure 8).

A typical time course to a series of injections is shown in
figure 9.

Substance P produced maximal miosis after intra-

vitreal injections of 1.0

(n=l)

and 0.1

(n=2)

yg.

Results were analyzed in the same manner as described
above for in vitro pupillary responses.
used in the in vivo experiments,
miosis,

ADH activity,

sorted out

Because DDAVP was

the relationships between

and pressor activity could be clearly

(figures 10 and 11).

While there was a relatively

high correlation between miosis and pressor activity
(R = 0.732,

p <

.001)

there was no significant correlation

between miosis and ADH activity (R = 0.27, p =

.16).

A

high correlation was also found between miosis and oxytocic
activity

(R =

.749,

p <

.001), but this relationship is

accounted for by high covariance between pressor activity
and oxytocic activity in the peptides used in vivo
0.613).

(R =

Moreover, multiple linear regression reveals no

■

..
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significant partial correlation coefficient for oxytocic
activity

(R =

.292,

p =

.132), whereas the partial correla¬

tion for pressor activity is significant
Interestingly,

(R =

.568,

p <

.002).

the "Lineweaver-Burk" analysis dis¬

played best the superiority of the relationship between
miosis and pressor activity.
lation coefficients were:
.001;

The respective bivariate corre¬

for pressor activity

for ADH activity 0.543, p =

activity

.238, p =

.263.

.708, p <

.006 and for oxytocic

Furthermore,

it should be noted

that the correlation coefficient for ADH activity is only
due to very high covariance with pressor activity
When a "V

max

" of 6mm miosis was assigned,
°

4.8 mUnits pressor activity

(.932).

a "K " of 24.6 +
m
—

(corresponding to 57 nanograms

of AVP) was obtained.

Effects of Neurohypophyseal Peptides on IOP in the Rabbit
DDAVP does not appear to affect IOP significantly at
the doses used

(.01,

.1 and lug)

for intravitreal injections

(Table 3).
LVP
animals

(0.2 units) produced a small fall in IOP in two

(4.5 + 2.13 mmHg);

the response was maximal about

two hours after the injection.
oxytocin produced a rise in IOP
animals.

In contrast,
(4.5 + 0.71

2.5 units of
mm Hg)

In one animal the IOP increase peaked at 2,

in two
9,

and 27 hours while in the other animal the maximum increase
occurred only at 27 hours;

IOP returned to baseline by 36

•
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hours in both.

There was no consisent relationship between
A

IOP response and miosis.

Therefore,

the unusual time course

of the response and its occurrence in only two animals make
it difficult to draw any conclusions from the data concern¬
ing the effect of oxytocin on IOP.
Otherwise, because of large standard errors and small
sample size, no significant patterns emerge. Multiple linear
regression analysis reveals no significant correlations be¬
tween IOP changes and pressor, ADR,

or oxytocic activity,

nor any significant relation between miosis

and IOP.

The substance P injections all produced transient
increases in IOP
maximal moisis.

(7 + 0.4mm Hg),

coincident with onset of

Stjemschantz et_ al have shown that this

increase in IOP is probably secondary to pupillary block.^

Page 49

DISCUSSION

Response of the Rabbit Iris to Neurohypophyseal Peptide
The neurohypophyseal peptides are known to contract
smooth muscle in a variety of tissues

(see Introduction).

Their contractile effects in vascular smooth muscle are
thought to be mediated directly by an increase in the cyto¬
solic concentration of calcium ions.^
The present work clearly demonstrates that the neuro¬
hypophyseal peptides exert potent contractile action on the
sphincter muscle of the rabbit iris;
of Swan and Meyer with Pitressin.

40

this

confirms the work

Schlaeppi also observed

miosis with large doses of Pitressin, but he reported that
both Pitocin and small doses of Pitressin

(0.05 units,

injected subconjunctivally) produced a weak mydriasis.

In

the present work oxytocin demonstrated only miotic activity
both in vivo
in vitro

(0.250 to 2.5 units,

(0.004 to 0.4 units/ml).

given intravitreally)
Furthermore,

as low as 0.02 units of LVP or 0.01 ug of DDAVP

and

even doses
(which

corresponds to only 0.00011 units of pressor activity)
produced no mydriasis in vivo, while AVP tested at concen¬
trations as low as 5 x 10
in vitro.

never caused any dilation

Nor were any effects on the isolated dilator

muscle observed.

Therefore,

the neurohypophyseal peptides

seem to exert their pupillary actions solely on the iris

■

.
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sphincter.
A variety of indirect mechanisms by which the neuro¬
hypophyseal peptides may produce their actions on the pupil
have been ruled out.

The lack of influence of indomethacin

pretreatment probably indicates that prostaglandins do not
mediate the response.

Because LVP, unlike bradykinin,

re¬

tained its miotic efficacy following capsaicin treatment,
it is unlikely that sensory neurotransmitters are signifi¬
cantly involved in the response.

Because the neurohy¬

pophyseal peptides were effective both in vivo and in vitro
the pupillary response is not related to actions on the vas
culature of the iris.

The response is also probably not

cholinergically mediated, because both Schlaeppi
Swan and Meyer
In conclusion,

42

41

and

reported it to be atropine resistant.

although several of the experiments in this

work must be considered preliminary,

it appears likely that

the neurohypophyseal peptides are acting directly upon the
smooth muscle of the iris sphincter.
This conclusion is further substantiated by the re¬
ceptor characteristics of the response.

Determination of

the identity of the receptor was based upon analysis of the
pupillary effects of several analogs in terms of their
known potencies in producing ADH, pressor,
effects.

or oxytocic

Such analysis is facilitated by the use of ana¬

logs with varying ratios of activities:
A:P and A:0 ratios)

e.g.

DDAVP

(high

and OT (high 0:A and 0:P ratios).

An

*
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even greater boon to receptor analysis is the possession of
a specific antagonist such as dCCt^)^-Tyr-(Me)-AVP, which
has an antivasopressor pA£ of 8.62 but does not antagonize
ADH effects;

in fact it possesses some small ADH activity

(0.31 units/mg).

Mediation of the miosis by a pressor-like

receptor was thus demonstrated in several ways:
1)

The elimination of in vitro responses

to LVP with the

vasopressor antagonist ruled out any possible significant
contribution of ADH activity
2)

toward producing miosis.

Within both mathematical models used for analysis of the

data,

(linear-logarithmic and "Michaelis-Menten"-"Lineweaver-

Burk"),

the in vitro pupillary constrictions correlated

with the concentration expressed as units of pressor activity
per liter

(R = 0.82, p

<

.001 and R = 0.83,

p <.001,

respec¬

tively).

Furthermore, multiple linear regression within

both models reveals a highly significant partial correla¬
tion coefficient for pressor activity

(R = 0.78,

and R = 0.72, p <

in contrast to that

.001,

respectively)

p <

.001

for oxytocic activity (R = 0.19, p = 0.26 and R = 0.41,
p =

.02,

respectively).

3)

The range of structural analogs used in the in vivo

experiments

(DDAVP, LVP,

OT, AVT),

facilitated elimination

of both oxytocic activity and ADH activity as contributing
to the response.

Multiple linear regression revealed that

pressor activity had an important independent contribution
to predicting miotic response

(p <

.002), whereas both ADH

*
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activity and oxytocic activity were not independently pre¬
dictive .
Because receptor-characterization portrays the miosis
as a pressor-like effect,

a mechanism of action on the iris

sphincter muscle analogous to that in vascular smooth muscle
is favored.

Effects of the Neurohypophyseal Peptides on 10P
The fall in IOP noted upon intravitreal administration
of a supraphysiologic dose of LVP

(0.2 units)

in two animals

is in agreement with a number of previous studies in which
large doses of Pitressin or LVP were administered by a
variety of routes.

In order to shed some

light on the mechanism of this effect,

DDAVP was administer¬

ed intravitreally in a total of 13 animals,
doses corresponding to
.00011 to

in a range of

.04 to 4 units of ADH activity and

.011 units of pressor activity.

effect on IOP was noted (Table 3),

Because no

it is unlikely that an

ADH receptor mediated mechanism is responsible for vaso¬
pressin's classic pharmacologic hypotensive effect.

This

conclusion is consistent with the failure of Gregory et al
to demonstrate significant adenylate cyclase activation
by vasopressin in ciliary epithelium.

73

However,

although

an action on ciliary epithelium mediated by another second
messenger has not been ruled out,

it seems that some more

plausibility is now established for the argument that

;
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vascular effects might mediate the pharmacologic effect of
vasopressin on IOP.

44,46,47,48,56

The present work has made no direct attempt to inves¬
tigate physiological actions of vasopressin on IOP.

Nor

has a physiologic role for an ADH receptor mediated action
on the ciliary epithelium been ruled out by the negative
results with DDAVP,

since circulating levels of endogenous

hormones may have already been sufficient to produce maximal
epithelial effects in the experimental animals.
The dearth of literature concerning intraocular ac¬
tions of oxytocin and vasotocin has already been mentioned.
The isolated finding obtained with these hormones in the
present study represent only a preliminary attempt to in¬
vestigate their effects on IOP.
to draw any further conclusions

It is especially difficult
concerning the effects of

neurohypophyseal hormones on IOP because statistical analysis
failed to establish any significant trends relating IOP
changes to either ADH, pressor,

or oxytocic activity.

Effects of Other Neuropeptides on the Iris

In the present work,

the pupillary effects of the

neurohypophyseal peptides were compared to those of several
other neuropeptides.
Substance P has proven to be useful in assessing the
pupillary effects of the neurohypophyseal peptides in
several ways.

Its known potent actions on the pupil were

.
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used to confirm adequate pharmacologic delivery of neuropep¬
tides from intravitreal injections.^5^>71,74

Furthermore,

the dose-response curve obtained with substance P in this
author's hands could be compared to results published in
the literature to assess the general reliability and accuracy
of the in vitro pupillometric system.^
Substance P is especially interesting in that it has
so much in common with the neurohypophyseal peptides.
have similar molecular weights

Both

(v 1380 for substance P,

%1080 for vasopressin); both constitute a family of structur¬
al analogs widely distributed among vertebrates:

1,75

may be CNS neurotransmitters or "neuromodulators,"

both

76 77
’

and

both produce complex behavioral effects that interact significantly with opiates.

In certain respects they

appear to be physiological antagonists:
a potent vasodilator
or;

79

substance P is

while vasopressin is a vasoconstrict-

substance P potentiates opiate analgesia in low doses,

while vasopressin seems to promote opiate tolerance;

78

26

substance P generally promotes diuresis and natriuresis
while vasopressin is potently antidiuretic.

85

The two peptides have very similar effect on the
rabbit iris.

Both seem to exert their effects directly on

the smooth muscle of the iris sphincter. Moreover,
seem to display very similar potencies in vitro.
in vivo studies,

on the other hand,

they

The

indicated that sub¬

stance P may exert a somewhat more protracted effect on the

‘

.
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pupil than vasopressin;

this observation may be related to

differential vulnerability of the peptides to enzymatic
degradation in the vitreous.
The major difference between the pupillary effects of
the two peptides lies in their physiologic role.

Substance

P has been demonstrated by radioimmunoassay both in the
normal rabbit iris

81

and in the aqueous humor following

antidromic stimulation of the trigeminal nerve.^
fore,

its miotic action probably plays a physiologic role,

most likely in the ocular nociceptive response.
hand,

There¬

On the other

comparable data concerning the presence of neurohy¬

pophyseal hormones in the eye are not available;

the exis¬

tence of a locus of these hormones containing sufficient
amounts to cause miosis is a highly speculative and unlikely
conjecture.

Vasopressin exerts its maximal antidiuretic

action at plasma levels on the order of 10
maximal hypovolemic stimulus

-12

M.

12

Even a

to vasopressin release does

not produce levels much in excess of 5 x 10

-11
3
" M,
which

is below the in vitro threshold concentration for AVP's
effects and much lower than the in vivo "K " for AVP of
—

1.4 x 10

-

8

-

m

M (calculated by assuming a volume of 4 ml for

the rabbit eye).

Therefore,

in contrast to substance P,

the miotic effects of the neurohypophyseal peptides are
probably of no physiologic significance in mammals.
Interestingly,

the 4-11 octapeptide fragment of

substance P also constricts the isolated iris;

in fact its
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potency may even be slightly greater than the native pep¬
tide in vitro.

This raises the possibility of using structur¬

al analogs to substance P to help sort out complex physiolog¬
ic effects in a manner analagous to the experimental applica¬
tions of neurohypophyseal hormone analogs.
It should also be noted that substance P-octapeptide
helped demonstrate the pressor receptor specificity of the
inhibitory effects of dCCIb,)^-Tyr-(Me)AVP.

Because the

response of the isolated iris to substance P-octapeptide was
not diminished by concentrations of dCCI^) ^-Tyr- (lie)
completely blocked the effects of LVP,

AVP that

one can conclude

that substance P and vasopressin exert their direct smooth
muscle actions on the iris sphincter through different
receptors.
The in vitro pharmacological activity of bradykinin
presented a striking contrast to that of vasopressin or
substance P by displaying marked tachyphylaxis and vulner¬
ability to capsaicin-induced desensitization.

Interestingly,

Cole and Unger also commented on the tachyphylaxis to brady¬
kinin 's effects on IOP and the pupil in experiments employing closed circuit intracameral perfusion in vivo.

82

This

marked tachyphylaxis is suggestive of bradykinin-induced
depletion of a limited endogenous pool of mediators of its
response.

Eakins et al

83

reported that indomethacin pre¬

treatment markedly inhibited bradykinin’s stimulation of
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miosis and increase in aqueous humor protein;

they there¬

fore argued in favor of a role for prostaglandins in mediat¬
ing bradykinin's response.

However,

the present work found

that indomethacin pre-treatment of the rabbit with a dose
(50mg/kg intravenously administered)

previously demonstrated

to completely inhibit cyclooxygenase,
bradykinin-induced miosis;
Cole and Unger,

82

84

has no effect on

this finding is

in agreement with

who also noticed no blockade of brady¬

kinin's actions on the eye by indomethacin.
The observation of in vitro capsaicin-induced desen¬
sitization of the iris to bradykinin is consistent with the
putative mediation of bradykinin's nociceptive actions by
sensory neurotransmitters . ^ ^ > 74

-j^is finding also helps

assure the effectiveness of capsaicin in producing pharma¬
cological "sensory denervation," and

therefore helps to

rule out a sensory nerve component to vasopressin's actions
on the pupil.
Neurotensin,

a recently isolated tridecapeptide with

a widespread CNS distribution similar but not identical to
that of enkephalin, has a broad spectrum of pharmacologic
activities

(hypothermia, hypotension, hyperglycemia,

hormone and prolactin release);

growth

its presence in the eye

(the amacrine cells of the pigeon retina)

and its potent

capillary permeability-increasing effects have made it an
attractive candidate for mediator of ocular nociceptive
responses.

79,86

This peptide, however,

exerted

only weak
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miotic effects on the isolated iris with a potency at least
two orders of magnitude less than that of substance P or
AVP.
A number of indirect and direct mechanisms have been
ascribed to the pupillary effects of morphine;

87

this

multiplicity of mechanisms apparently accounts for the great
interspecies variability of its effects on the pupil.

Opiates

cause prominent centrally-mediated miosis in man and dogs,
but they cause mydriasis in cats by causing adrenal medullary
release of epinephrine.

88

Recently,

a child with subacute

necrotizing encephalomyelopathy was reported to have re¬
markably elevated levels of endophins

(especially enkephalins

in the CSF and in the post-mortem brain.

89

The child had

suffered from neurological attacks which were reminiscent
of morphine-overdose and which were often partially allev¬
iated by naloxone.

A naloxone-reversible miosis was con¬

sistently noted during these attacks.

This fascinating case

suggests that endogenous opiates are involved in pupil regulation--at least in certain pathological states.

89a

The

present study failed to detect any in vitro pupillary
effects of m et-enkephalin,

thus favoring a central media¬

tion of enkephalin-induced miosis.

Suggestions for Future Experiments

The present work highlights several approaches that
can be used to study physiologic actions on IOP and the pupil

,

.
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The wide range of structural analogs now available
can be used to determine whether the neurohypophyseal
hormones have significant physiologic effects on IOP.

An

optimal approach would combine the use of these analogs with
some method to prevent the interference of endogenous vaso¬
pressin or oxytocin.

Antagonists such as d(CH)(Me)-AVP

would be useful in eliminating pressor or oxytocic components of this interference;

59

investigation of the in

vivo actions of these antagonists alone would determine
whether endogenous pressor or oxytocic activity played a
significant role in regulation of IOP.

However,

greater

difficulty is encountered when trying to remove interfering
influences of endogenous ADH activity, because at present
there is no specific ADH antagonist available.

Several

approaches to handling this problem do seem feasible.
51,53
Ethanol loading has already been used with some success'
however, because ethanol possesses its own smooth muscle
and metabolic effects,

another agent may be desirable.

Possible alternatives are phenytoin, which also inhibits

3
release of ADH

,

and somatostatin, which inhibits vaso¬

pressin-induced activation of adenylate-cyclase in toad
bladder epithelium.

90

Once a reliable method for removing interfering in¬
fluences of endogenous vasopressin activity has been es¬
tablished,

structural analogs such as DDAVP can be used

to characterize the receptor mediation of the IOP response

'

.

’
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in an approach analogous to the one used here to character¬
ize the pupillary response.

The pupil's response may even

prove to be a useful indicator of pharmacologic delivery
of peptides that have inherent pressor activity,
be a useful guide as

and may

to whether vascular effects are being

exerted.
Preliminary experiments have also illustrated how
capsaicin-induced desensitization of the in vitro isolated
preparation can be successfully implemented to study sen¬
sory neurotransmitter mediation of pupillary responses.
An advantage of this system is the ease with which the
desensitization can be assessed by monitoring the loss of
pupil responsiveness

to capsaicin.

Additional experiments

are needed to confirm the efficacy of this technique in
producing sensory nerve terminal depletion of neurotrans¬
mitters.

This could be accomplished either by using a

radioimmunoassay or ELISA technique to directly assay neuro
transmitter release in the perfusate and neurotransmitter
depletion in the iris,

or by demonstrating effectiveness

in eliminating in vitro responses to other known neurallymediated agents,

such as nitrogen mustard or formalde-

hyde.91'92
The system is also well-suited to study mechanisms of
release of putative sensory neurotransmitters such as sub¬
stance P.

Given a sufficiently sensitive neuropeptide

iris

-

'
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assay,

the continuous perfusion apparatus of the in vitro

system makes it possible to correlate time course of neuro¬
transmitter release with pupil response.

Direct demonstra¬

tion that nociceptive agents such as bradykinin or prostaglandins

93 94
’
act by releasing peptides such as substance P

would have broad implications for future pharmacologic
approaches to analgesic and anti-inflammatory therapy.

-
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TABLE

1

SPECIFIC ACTIVITIES OF NEUROHYPOPHYSEAL PEPTIDES USED

Source

Peptide

Rat Antidiuresis
(units/mg)

AVP

350

70

350

supplier

AVT

255

220

260

Berde and ^
Boissonnas

LVP

100

22.5

100

supplier

3.2

11

Vavra,

500

5

supplier

DDAVP

Rabbit Milk
Ejection
(units/mg)

870-4000

OT

5

Rat Pressor
(units/mg)

et. al^

[d(CH2)5Tyr(Me)AVP]
1
2
3
4
5
6
7
6
9
CH2-CC-Tyr(r. e)-Phe'Gln- Asn- Cy -Pro* Arg Gly - NHp

ch2ch2

c<

j

>
ch2ch2 j

(a)

s—
l

H—C—H

I

H—C—H

I
o=c-

D-Aro

1 -Deomino-S p-Arc; nine Vcsop'essin
(desmopressin, c'DAVPj

aFrom M.

Kruszynski,

et aU.

J.

Med.

(b)

Chem.

23:

1980,

p.365.

From R.M. Hays, in Goodman and Gilman's; The Pharmacological
Basis of Therapeutics, 6th ed. (New York: Macmillan,
1980), p. 917.
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TABLE

POSSIBLE MECHANISMS BY WHICH
INFLUENCE

Inflow

2

NEUROHYPOPHYSEAL PEPTIDES MAY

INTRAOCULAR PRESSURE

Possible Sites of Action
on IOP

Possible Vasopressin
Anesthesia Interactions

Plasma osmolarity

known to cause ADH
release

i

Volume changes secondary
to vascular effects
Probably
only
Transient
and
Volumetric
Ef f ects

Ciliary arteriole perfusion
pressure
-local vasoconstriction
arteriole

known to alter local
vascular tone and
reflexes®^

metarteriole
post-capillary
venule

V.

-systemic pressor
effect

Ciliary epithelial
transport or water
permeability

Outflow

Outflow Facility
Pupillary block?
Episcleral venous pressure?

known to enhance pressor
effect

Page

TABLE

Effects of

3

Intravitreal Administration of Neurohypophyseal

Peptides on Intraocular Pressure

Peptide
AVT

LVP

OT

DDAVP

AIOP

Dose

<£MOP mmHg

S.E.M.

0. lug

+2

7.07

1. Opg

+5a

0.2IU

-4.^

2.12

2

0.1IU

0.0

5.66

2

at 2,

9,

2

0.02IU

0.5

4.95

2

0.25IU

-1.5

2.12

2

0.5IU

-1.5

4.95

2

1.0IU

0.0

1.41

2

2.5IU

+4.5C

0.71

2

1. Opg

-0.6

1.19

7

0. ljug

-1.3

0.81

3

0.Olpg

-1.0

1.22

3

in IOP observed

(right eye

following intravitreal administration of peptide

in the right eye and
(a)

Number of Animals

1

is the maximal difference

left eye)

in the Rabbit

noted at
and

saline

5 hours;

27 hours.

in the
(b)

left eye.

noted

at

2 hours;

(c)

noted

*
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FIGURE

DISTRIBUTION OF

THE

1

NEUROHYPOPHYSEAL HORMONES AMONG

VERTEBRATES

MAMMALS
A VP, AVT, LVP.OT
HOLOCEPHALANS 7 AVT, OT

4-Serine peptides*

4-Glutamine peptides

GT* Giumitocin
IT * Isotocin

AVT * Arginine-vasotocin
AVP« Arginine-vasopressin
OT * Oxytocin
MT * Mesotocin
VT « Volitocin
LVP* Lysine-vasopressin

4-Asparagine peptide**
AT» Aspartocin

Underlined

principles

in

representing

species

have
the

been

chemically

indicated

identified

groups.

TABLE 1. The known naturally occurring
active neurohypophysial peptides
Amino acid in
positions
Peptide
1

\

5

L

Phe
Phe
lie

Gin
Gin
(.In

Arg
Lvs
Arg

lie
He
He
He
He
He

Gin
Gin
Ser
.Set
Asn
Gin

Leu
He
He
Gin
Leu
Val

'tisupressur prptuh'S

Argimne-sasopressin
L\ sine-vasopressin
Arginine-vasotocin
0\\tin in-likf
()\\toe in
Mesotocin
Isotocin
Glmnitoc in
Aspartocin
Valilot in
Common sinulure:

i
C\S-

I

———1

r>r-\—V-Asrv('.vS-Pr«*-Z-Gly(NV,)
234 5 6789

From W.H.
Proc. 36:

Sawyer.
Federation
1977, p.1843.

.

•-
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FIGURE 2
RESPONSES OF ISOLATED IRIS TO NEUROHYPOPHYSEAL PEPTIDES

(

)

refers to number of animals used for determination;

unless

otherwise indicated, N = 1.
Responses to Substance P

(SP)

are included for comparison.

■
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Figure 3

Response of Isolated

Iris to 60 Second

Infusions of Oxytocin

0.01

Changes

lU/ml

0.02

0.16 mm

in Diameter

lU/ml

0.04 lU/ml

0.28 mm

0.52 mm

TIME

—>

Recorder output from spectrophotometer showing
change in light absorbance
second

in response to 60

infusions of oxytocin.

6 minutes per inch

Time

scale is

(2 minutes per division).

Initial pupil diameter is 3.99 mm.

.
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FIGURE 4

RESPONSE OF ISOLATED IRIS TO fCUROWtPOPKr'SEAL PEPTIDES

C
0

N
S
T
R
I
C
T

avp
0
avt
A

I
0

N
lvp

□

X

ot
A

"Peptide concentrations used
converted
Figure

2

in 60

second

to pressor units/liter and
replotted here accordingly.

the

infusions were
results shown in
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FIGURE 5

RESPONSE OF ISOLATED IRIS TO hELROHYPOPWl'SEAL PEPTIDES

C
0

N
5
T
R

I
C
T

0

I
0

av/t
A

N
Ivp

□

ot
A

LOG CONCENTRATION (60 tec. infusions) in OXYTOCIC UNITS/L

Peptide concentrations used
converted

in 60 second

to oxytocic units/liter and

in Figure 2

replotted

accordingly.

the

infusions were
results shown
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FIGURE

LINEWEAVER-BURK

ANALYSIS
OF

OF

VASOPRESSOR-INDUCED

ISOLATED

IRIS

PREPARATION

/

%

Constriction

CONSTRICTION

6

The

relationship

dose
the

(S)
form

'V

** was
max
equation

between

in

pressor

of

the

pupillary

units

(see

constriction

Figure

4)

Lineweaver-Burk. equation:

is

(V)

and

expressed

t;=K {7;
V
m V

max

) (-p)
S

assigned at 90% constriction, and
^
converted to the form: V
/V - 1 = K (1/S).
max
m
equation was fitted by linear regression to a line
through
qives

3

arbitrarily

J

the

the

origin

best

(dotted

fitted

value

line).
for

"K

The

m

."

slope

of

the

in
+

7;
-V

the
This

line

max.

.
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FIGURE

TACHYPHYLAXIS

OF

RESPONSE

7

TO BRADYKININ

IN

ISOLATED

IRIS

% PUPILLARY CONSTRICTION

PREPARATION

DOSE
Each

line

separate
*

represents

the

results

obtained

from

a

preparation.

indicates

that

Tween-20 was

included

in

the

buffer.

'
■
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FIGURE

MIOSIS

RESULTING

FROM

85

8

INTRAVITREAL

INJECTION

OF VASOPRESSIN

PUPIL CONSTRICTION, mm
(Right Eye—Left Eye)

PEPTIDES

DOSE (ng)
(

)

refers

Responses

to
to

number

of

substance P

animals;
(SP)

are

n=2

unless

included

otherwise
for

specified.

comparison.

Page

FIGURE

TIME

COURSE

OF MIOSIS

86

9

FOLLOWING

INTRAVITREAL

INJECTIONS

OF

PUPIL DIAMETER, mm
(Right Eye-Left Eye)

r

04* □

-2

-

-3
-4

A □

A

□

CD

A

□

□A

CA

□

□
A

□

m a

• 0.2 units LVP
A 0.1 units LVP
□ 0.02 units LVP

• •
A

-5

•

I
13

•
• A

5

JL
15

10

20

HOURS POST INTRAVITREAL INJECTION

The

graph

produced

demonstrates
an

earlier

that

onset

of

the

larger

miosis.

doses

of

LVP

22

LVP
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FIGURE

87

10

IN VIVO MIOSIS AND PRESSOR ACTIVITY

avt

0
lvp

A
ot

□

ddavp
A
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FIGURE

11

IN VIVO MIOSIS AND ADH ACTIVITY

avt
$

lvp
A
ot

□

ddavp
A

DOSE (intravitreal injection) in LOG ADH UNITS
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